What trials examined RASi as agents used to reduce kidney disease progression?
A fair number of trials examined RASi as agents used to reduce kidney disease progression in people with and without high BP, and/or with and without diabetes. These include the HOPE trial, which examined ACEi as CV protective agents in people with and without high BP and included a minority with CKD. Lowering of BP was explicitly not the aim of those trials.